{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T23:56:12Z","timestamp":1790898972565,"version":"4.1.0"},"reference-count":92,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:00:00Z","timestamp":1789776000000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Idiopathic inflammatory myopathies (IIMs) follow a chronic, polycyclic course in a substantial proportion of patients. Unlike remission, which has recently been standardized, the definition of flare (or worsening) remains highly heterogeneous, creating a divide between clinical trials and real-world practice. Validated core set definitions of worsening exist for trials but were derived by consensus on paper patient profiles and are criticized for inadequate content validity; observational studies instead rely on simplified markers such as enzyme elevation or therapeutic escalation. This review summarizes existing definitions, contrasting the International Myositis Assessment and Clinical Studies Group and Paediatric Rheumatology International Trials Organisation statistical criteria with the variable definitions used in longitudinal cohorts. We examine reported flare rates and predictors, the discordance between global and organ-specific (skin, muscle, lung) worsening, and the lessons offered by flare definitions in other rheumatic and inflammatory diseases. We then propose a multi-domain, treatment-anchored framework intended to bridge statistical rigour and clinical utility.<\/jats:p>","DOI":"10.1093\/rheumatology\/keag522","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T19:12:58Z","timestamp":1789672378000},"source":"Crossref","is-referenced-by-count":0,"title":["Flares and definition of worsening in inflammatory myopathies: a narrative review of the literature"],"prefix":"10.1093","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-1921-7370","authenticated-orcid":false,"given":"Maria Rosa","family":"Pellico","sequence":"first","affiliation":[{"name":"Clinical Rheumatology Unit, ASST Gaetano Pini\u2013CTO Institute , Milan,","place":["Italy"]},{"name":"Department of Clinical Sciences and Community Health, Research Center for Adult and Pediatric Rheumatic Diseases, University of Milan , Milan,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4077-1374","authenticated-orcid":false,"given":"Mert","family":"\u00d6zta\u015f","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Ac\u0131badem University School of Medicine, Ac\u0131badem Atakent Hospital , Istanbul,","place":["Turkey"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2753-2990","authenticated-orcid":false,"given":"Latika","family":"Gupta","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Royal Wolverhampton NHS Trust , Wolverhampton,","place":["United Kingdom"]},{"name":"The Francis Crick Institute , London,","place":["United Kingdom"]},{"name":"Department of Inflammation and Ageing, School of Infection, Inflammation and Immunology, University of Birmingham , Birmingham,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,18]]},"reference":[{"key":"2026100119511907500_keag522-B1","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s41572-021-00321-x","article-title":"Idiopathic inflammatory myopathies","volume":"7","author":"Lundberg","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"2026100119511907500_keag522-B2","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1136\/ard.2005.045690","article-title":"Long-term outcome in polymyositis and dermatomyositis","volume":"65","author":"Bronner","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"2026100119511907500_keag522-B3","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1002\/(SICI)1097-4598(199812)21:12<1668::AID-MUS7>3.0.CO;2-#","article-title":"Frequency of relapses in patients with polymyositis and dermatomyositis","volume":"21","author":"Phillips","year":"1998","journal-title":"Muscle Nerve"},{"key":"2026100119511907500_keag522-B4","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1093\/rheumatology\/40.11.1262","article-title":"Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies","volume":"40","author":"Miller","year":"2001","journal-title":"Rheumatology"},{"key":"2026100119511907500_keag522-B5","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/art.23248","article-title":"The provisional Paediatric Rheumatology International Trials Organisation\/American College of Rheumatology\/European League against rheumatism disease activity core set for the evaluation of response to therapy in juvenile dermatomyositis: a prospective validation study","volume":"59","author":"Ruperto","year":"2008","journal-title":"Arthritis Rheum"},{"key":"2026100119511907500_keag522-B6","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/nrrheum.2018.33","article-title":"Update on outcome assessment in myositis","volume":"14","author":"Rider","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"2026100119511907500_keag522-B7","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1136\/annrheumdis-2017-211868","article-title":"The EuroMyositis registry: an international collaborative tool to facilitate myositis research","volume":"77","author":"Lilleker","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2026100119511907500_keag522-B8","first-page":"50","article-title":"Disease course, frequency of relapses and survival of 73 patients with juvenile or adult dermatomyositis","volume":"23","author":"Ponyi","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"2026100119511907500_keag522-B9","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1111\/j.1365-2133.2008.08711.x","article-title":"Comparison of the reliability and validity of outcome instruments for cutaneous dermatomyositis","volume":"159","author":"Klein","year":"2008","journal-title":"Br J Dermatol"},{"key":"2026100119511907500_keag522-B10","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1111\/bjd.13915","article-title":"Validation of the Cutaneous Dermatomyositis Disease Area and Severity Index: characterizing disease severity and assessing responsiveness to clinical change","volume":"173","author":"Anyanwu","year":"2015","journal-title":"Br J Dermatol"},{"key":"2026100119511907500_keag522-B11","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1007\/s10067-005-0075-3","article-title":"Characterization of relapses in adult idiopathic inflammatory myopathies","volume":"25","author":"Agarwal","year":"2006","journal-title":"Clin Rheumatol"},{"key":"2026100119511907500_keag522-B12","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1111\/jdv.13516","article-title":"Dermatomyositis: factors predicting relapse","volume":"30","author":"Vuong","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026100119511907500_keag522-B13","first-page":"21","article-title":"Predictive factors for relapse in adults with dermatomyositis","volume":"29","author":"Titou","year":"2020","journal-title":"Acta Dermatovenerol Alp Pannonica Adriat"},{"key":"2026100119511907500_keag522-B14","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1080\/14397595.2017.1317377","article-title":"Anti-SS-A\/Ro antibody positivity as a risk factor for relapse in patients with polymyositis\/dermatomyositis","volume":"28","author":"Tatebe","year":"2018","journal-title":"Mod Rheumatol"},{"key":"2026100119511907500_keag522-B15","first-page":"2230","article-title":"Polymyositis and dermatomyositis: short term and longterm outcome, and predictive factors of prognosis","volume":"28","author":"Marie","year":"2001","journal-title":"J Rheumatol"},{"key":"2026100119511907500_keag522-B16","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s00296-020-04779-y","article-title":"Characteristics and outcomes of overlap myositis: a comparative multigroup cohort study in adults from the MyoCite cohort","volume":"41","author":"Naveen","year":"2021","journal-title":"Rheumatol Int"},{"key":"2026100119511907500_keag522-B17","doi-asserted-by":"crossref","first-page":"e70446","DOI":"10.1111\/ene.70446","article-title":"Prognostic implications of myositis-specific autoantibodies on mortality, relapse, and remission in dermatomyositis patients","volume":"32","author":"Hou","year":"2025","journal-title":"Eur J Neurol"},{"key":"2026100119511907500_keag522-B18","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jaad.2022.03.054","article-title":"Preliminary definition of cutaneous flare in dermatomyositis: a retrospective review","volume":"88","author":"Dan","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"2026100119511907500_keag522-B19","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1186\/ar3531","article-title":"Type I interferon pathway in adult and juvenile dermatomyositis","volume":"13","author":"Baechler","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"2026100119511907500_keag522-B20","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/j.1529-8019.2012.01491.x","article-title":"Management of cutaneous dermatomyositis: management of cutaneous dermatomyositis","volume":"25","author":"Lam","year":"2012","journal-title":"Dermatol Ther"},{"key":"2026100119511907500_keag522-B21","doi-asserted-by":"crossref","first-page":"434","DOI":"10.21037\/atm-20-3719","article-title":"Environmental triggers of dermatomyositis: a narrative review","volume":"9","author":"Bax","year":"2021","journal-title":"Ann Transl Med"},{"key":"2026100119511907500_keag522-B22","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s004150200036","article-title":"Seasonal occurrence of relapses in inflammatory myopathies: a preliminary study","volume":"249","author":"Phillips","year":"2002","journal-title":"J Neurol"},{"key":"2026100119511907500_keag522-B23","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1093\/rheumatology\/41.9.1040","article-title":"Inflammatory myositis associated with anti-U1-small nuclear ribonucleoprotein antibodies: a subset of myositis associated with a favourable outcome","volume":"41","author":"Coppo","year":"2002","journal-title":"Rheumatology"},{"key":"2026100119511907500_keag522-B24","doi-asserted-by":"crossref","first-page":"e96","DOI":"10.1212\/NXI.0000000000000096","article-title":"Clinical course and treatment of anti-HMGCR antibody-associated necrotizing autoimmune myopathy","volume":"2","author":"Ramanathan","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2026100119511907500_keag522-B25","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s10067-017-3854-8","article-title":"Risk factors for the recurrence of interstitial lung disease in patients with polymyositis and dermatomyositis: a retrospective cohort study","volume":"37","author":"Nakazawa","year":"2018","journal-title":"Clin Rheumatol"},{"key":"2026100119511907500_keag522-B26","doi-asserted-by":"crossref","first-page":"1666332","DOI":"10.3389\/fmed.2025.1666332","article-title":"Clinical features and recurrence risk prediction model in patients with idiopathic inflammatory myopathies-associated interstitial lung disease: a retrospective study from Ningbo","volume":"12","author":"Wu","year":"2025","journal-title":"Front Med (Lausanne)"},{"key":"2026100119511907500_keag522-B27","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.resinv.2019.10.004","article-title":"Predictive factors for the recurrence of anti-aminoacyl-tRNA synthetase antibody-associated interstitial lung disease","volume":"58","author":"Takei","year":"2020","journal-title":"Respir Investig"},{"key":"2026100119511907500_keag522-B28","doi-asserted-by":"crossref","first-page":"e003121","DOI":"10.1136\/rmdopen-2023-003121","article-title":"Interstitial lung disease with and without progressive fibrosing phenotype in patients with idiopathic inflammatory myopathies: data from a large multicentric cohort","volume":"9","author":"Zanatta","year":"2023","journal-title":"RMD Open"},{"key":"2026100119511907500_keag522-B29","doi-asserted-by":"crossref","first-page":"1404828","DOI":"10.3389\/fimmu.2024.1404828","article-title":"Prognostic significance of natural killer cell depletion in predicting progressive fibrosing interstitial lung disease in idiopathic inflammatory myopathies","volume":"15","author":"Shao","year":"2024","journal-title":"Front Immunol"},{"key":"2026100119511907500_keag522-B30","doi-asserted-by":"crossref","first-page":"3690","DOI":"10.1093\/rheumatology\/kead122","article-title":"Quantitative interstitial lung disease scores in idiopathic inflammatory myopathies: longitudinal changes and clinical implications","volume":"62","author":"Yeo","year":"2023","journal-title":"Rheumatology"},{"key":"2026100119511907500_keag522-B31","doi-asserted-by":"crossref","first-page":"872615","DOI":"10.3389\/fimmu.2022.872615","article-title":"Clinical features, prognostic factors, and survival of patients with antisynthetase syndrome and interstitial lung disease","volume":"13","author":"Zhao","year":"2022","journal-title":"Front Immunol"},{"key":"2026100119511907500_keag522-B32","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1016\/j.jid.2023.05.025","article-title":"Validation of cutaneous dermatomyositis disease area and severity index activity score and other efficacy outcomes as measures of skin disease in dermatomyositis in the lenabasum phase 3 trial","volume":"143","author":"Pandya","year":"2023","journal-title":"J Invest Dermatol"},{"key":"2026100119511907500_keag522-B33","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3389\/fmed.2020.00012","article-title":"Acute exacerbation of interstitial lung disease in adult patients with idiopathic inflammatory myopathies: a retrospective case-control study","volume":"7","author":"Liang","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"2026100119511907500_keag522-B34","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.3390\/diagnostics15192516","article-title":"The clinical features and prognosis of idiopathic and infection-triggered acute exacerbation of idiopathic inflammatory myopathy-associated interstitial lung disease: a preliminary study","volume":"15","author":"Zhang","year":"2025","journal-title":"Diagnostics"},{"key":"2026100119511907500_keag522-B35","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1186\/s12890-025-03962-w","article-title":"Longitudinal change of idiopathic inflammatory myopathy-associated interstitial lung disease on high-resolution computed tomography, a prospective cohort study","volume":"25","author":"Qiang","year":"2025","journal-title":"BMC Pulm Med"},{"key":"2026100119511907500_keag522-B36","doi-asserted-by":"crossref","first-page":"213","DOI":"10.46497\/ArchRheumatol.2024.10418","article-title":"Predictive risk factors for one-year mortality in idiopathic inflammatory myopathy patients with interstitial lung disease: a retrospective, single-center cohort study","volume":"39","author":"Jiang","year":"2024","journal-title":"Arch Rheumatol"},{"key":"2026100119511907500_keag522-B37","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/s12890-016-0325-y","article-title":"Long-term clinical course of anti-glycyl tRNA synthetase (anti-EJ) antibody-related interstitial lung disease pathologically proven by surgical lung biopsy","volume":"16","author":"Sasano","year":"2016","journal-title":"BMC Pulm Med"},{"key":"2026100119511907500_keag522-B38","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.semarthrit.2011.09.008","article-title":"Short-term and long-term outcome of anti-Jo1-positive patients with anti-Ro52 antibody","volume":"41","author":"Marie","year":"2012","journal-title":"Semin Arthritis Rheum"},{"key":"2026100119511907500_keag522-B39","doi-asserted-by":"crossref","first-page":"1407633","DOI":"10.3389\/fimmu.2024.1407633","article-title":"Poor prognostic factors for relapse of interstitial lung disease with anti-aminoacyl-tRNA synthetase antibodies after combination therapy","volume":"15","author":"Matsuda","year":"2024","journal-title":"Front Immunol"},{"key":"2026100119511907500_keag522-B40","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1093\/rheumatology\/keaa372","article-title":"Prognosis of adult idiopathic inflammatory myopathy-associated interstitial lung disease: a retrospective study of 679 adult cases","volume":"60","author":"Li","year":"2021","journal-title":"Rheumatology"},{"key":"2026100119511907500_keag522-B41","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1097\/MCP.0000000000001000","article-title":"Myositis-associated interstitial lung disease","volume":"29","author":"Vu","year":"2023","journal-title":"Curr Opin Pulm Med"},{"key":"2026100119511907500_keag522-B42","doi-asserted-by":"crossref","first-page":"6085","DOI":"10.3390\/jcm13206085","article-title":"Myositis-associated interstitial lung disease: the experience of a tertiary center","volume":"13","author":"Correia","year":"2024","journal-title":"J Clin Med"},{"key":"2026100119511907500_keag522-B43","doi-asserted-by":"crossref","first-page":"1325082","DOI":"10.3389\/fmed.2023.1325082","article-title":"Progressive pulmonary fibrosis in myositis-specific antibody-positive interstitial pneumonia: a retrospective cohort study","volume":"10","author":"Wang","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"2026100119511907500_keag522-B44","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1093\/rheumatology\/keae361","article-title":"Distinct phenotype and prognosis of immune-mediated necrotizing myopathy based on clinical\u2013serological\u2013pathological classification","volume":"64","author":"Yang","year":"2025","journal-title":"Rheumatology"},{"key":"2026100119511907500_keag522-B45","doi-asserted-by":"crossref","first-page":"6","DOI":"10.5414\/NP301077","article-title":"Idiopathic inflammatory myopathies overlapping with systemic diseases","volume":"37","author":"Lepreux","year":"2018","journal-title":"Clin Neuropathol"},{"key":"2026100119511907500_keag522-B46","doi-asserted-by":"crossref","first-page":"974078","DOI":"10.3389\/fimmu.2022.974078","article-title":"Scleromyositis: a distinct novel entity within the systemic sclerosis and autoimmune myositis spectrum. Implications for care and pathogenesis","volume":"13","author":"Giannini","year":"2022","journal-title":"Front Immunol"},{"key":"2026100119511907500_keag522-B47","first-page":"1424","article-title":"Patient-reported dermatomyositis and polymyositis flare symptoms are associated with disability, productivity loss, and health care resource use","volume":"26","author":"Christopher-Stine","year":"2020","journal-title":"J Manag Care Spec Pharm"},{"key":"2026100119511907500_keag522-B48","first-page":"265","article-title":"Work ability in patients with polymyositis and dermatomyositis: an explorative and descriptive study","volume":"53","author":"Regardt","year":"2015","journal-title":"Work"},{"key":"2026100119511907500_keag522-B49","doi-asserted-by":"crossref","first-page":"4845","DOI":"10.1093\/rheumatology\/keac161","article-title":"Investigating characteristics of idiopathic inflammatory myopathy flares using daily symptom data collected via a smartphone app","volume":"61","author":"Oldroyd","year":"2022","journal-title":"Rheumatology"},{"key":"2026100119511907500_keag522-B50","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.semarthrit.2021.03.018","article-title":"Utility of patient-reported outcomes measurement information system (PROMIS) physical function form in inflammatory myopathy","volume":"51","author":"Saygin","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"2026100119511907500_keag522-B51","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/s11926-019-0862-5","article-title":"Patient-reported outcomes in adult idiopathic inflammatory myopathies","volume":"21","author":"DiRenzo","year":"2019","journal-title":"Curr Rheumatol Rep"},{"key":"2026100119511907500_keag522-B52","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1136\/annrheumdis-2017-211400","article-title":"2016 American College of Rheumatology\/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis","volume":"76","author":"Aggarwal","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2026100119511907500_keag522-B53","doi-asserted-by":"crossref","first-page":"3672","DOI":"10.1093\/rheumatology\/kead110","article-title":"Performance of the 2016 ACR-EULAR Myositis Response Criteria in adult dermatomyositis\/polymyositis therapeutic trials and consensus profiles","volume":"62","author":"Saygin","year":"2023","journal-title":"Rheumatology"},{"key":"2026100119511907500_keag522-B54","first-page":"279","article-title":"Health-related quality of life improvements and response thresholds of myositis outcome measures and response criteria","volume":"44","author":"Almackenzie","year":"2026","journal-title":"Clin Exp Rheumatol"},{"key":"2026100119511907500_keag522-B55","doi-asserted-by":"crossref","first-page":"3379","DOI":"10.1007\/s10067-024-07120-1","article-title":"Relapse risk factors and clinical characteristics of idiopathic inflammatory myopathies in 105 patients","volume":"43","author":"Choi","year":"2024","journal-title":"Clin Rheumatol"},{"key":"2026100119511907500_keag522-B56","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1002\/acr.20280","article-title":"The Paediatric Rheumatology International Trials Organisation provisional criteria for the evaluation of response to therapy in juvenile dermatomyositis","volume":"62","author":"Ruperto","year":"2010","journal-title":"Arthritis Care Res"},{"key":"2026100119511907500_keag522-B57","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/rheumatology\/keg427","article-title":"International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease","volume":"43","author":"Isenberg","year":"2004","journal-title":"Rheumatology"},{"key":"2026100119511907500_keag522-B58","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.21037\/jtd-23-1736","article-title":"Predictors of relapse of polymyositis\/dermatomyositis associated interstitial lung disease","volume":"16","author":"Kishaba","year":"2024","journal-title":"J Thorac Dis"},{"key":"2026100119511907500_keag522-B59","first-page":"247","article-title":"Clinical phenotypes and long-term outcomes of anti-SRP versus anti-HMGCR immune-mediated necrotising myopathy: a 13-year single-centre study","volume":"44","author":"Clark","year":"2026","journal-title":"Clin Exp Rheumatol"},{"key":"2026100119511907500_keag522-B60","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/joim.12451","article-title":"Myositis-specific autoantibodies: an important tool to support diagnosis of myositis","volume":"280","author":"Betteridge","year":"2016","journal-title":"J Intern Med"},{"key":"2026100119511907500_keag522-B61","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1093\/rheumatology\/keq073","article-title":"Increased ferritin predicts development and severity of acute interstitial lung disease as a complication of dermatomyositis","volume":"49","author":"Gono","year":"2010","journal-title":"Rheumatology"},{"key":"2026100119511907500_keag522-B62","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1093\/rheumatology\/kes102","article-title":"Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis","volume":"51","author":"Gono","year":"2012","journal-title":"Rheumatology"},{"key":"2026100119511907500_keag522-B63","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3109\/s10165-010-0371-x","article-title":"Serum ferritin correlates with activity of anti-MDA5 antibody-associated acute interstitial lung disease as a complication of dermatomyositis","volume":"21","author":"Gono","year":"2011","journal-title":"Mod Rheumatol"},{"key":"2026100119511907500_keag522-B64","doi-asserted-by":"crossref","first-page":"773352","DOI":"10.3389\/fimmu.2021.773352","article-title":"Dermatomyositis with anti-MDA5 antibodies: bioclinical features, pathogenesis and emerging therapies","volume":"12","author":"Nombel","year":"2021","journal-title":"Front Immunol"},{"key":"2026100119511907500_keag522-B65","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/s13075-025-03675-9","article-title":"Baricitinib could improve the prognosis of anti-MDA5 antibody positive dermatomyositis associated interstitial lung disease","volume":"27","author":"Zhu","year":"2025","journal-title":"Arthritis Res Ther"},{"key":"2026100119511907500_keag522-B66","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12890-017-0479-2","article-title":"Clinical effects of direct hemoperfusion using a polymyxin B-immobilized fiber column in clinically amyopathic dermatomyositis-associated rapidly progressive interstitial pneumonias","volume":"17","author":"Okabayashi","year":"2017","journal-title":"BMC Pulm Med"},{"key":"2026100119511907500_keag522-B67","doi-asserted-by":"crossref","first-page":"387","DOI":"10.2169\/internalmedicine.8335-16","article-title":"The serum ferritin level is associated with the treatment responsivity for rapidly progressive interstitial lung disease with amyopathic dermatomyositis, irrespective of the anti-MDA5 antibody level","volume":"57","author":"Osawa","year":"2018","journal-title":"Intern Med"},{"key":"2026100119511907500_keag522-B68","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1080\/14397595.2018.1548918","article-title":"Serum neopterin as well as ferritin, soluble interleukin-2 receptor, KL-6 and anti-MDA5 antibody titer provide markers of the response to therapy in patients with interstitial lung disease complicating anti-MDA5 antibody-positive dermatomyositis","volume":"29","author":"Nishioka","year":"2019","journal-title":"Mod Rheumatol"},{"key":"2026100119511907500_keag522-B69","doi-asserted-by":"crossref","first-page":"9679944","DOI":"10.1155\/2024\/9679944","article-title":"An observational study on the clinical characteristics and prognosis of patients with interstitial lung disease secondary to dermatomyositis and antisynthetase syndrome","volume":"2024","author":"Lei","year":"2024","journal-title":"Int J Rheumatol"},{"key":"2026100119511907500_keag522-B70","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1136\/annrheumdis-2012-202281","article-title":"Construct and criterion validity of several proposed DAS28-based rheumatoid arthritis flare criteria: an OMERACT cohort validation study","volume":"72","author":"van der Maas","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2026100119511907500_keag522-B71","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1136\/ard-2023-224742","article-title":"Definition of rheumatoid arthritis flare based on SDAI and CDAI","volume":"83","author":"Konzett","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"2026100119511907500_keag522-B72","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1136\/annrheumdis-2017-212178","article-title":"An Assessment in SpondyloArthritis International Society (ASAS)-endorsed definition of clinically important worsening in axial spondyloarthritis based on ASDAS","volume":"77","author":"Molto","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2026100119511907500_keag522-B73","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1191\/096120399680411281","article-title":"Classification and definition of major flares in SLE clinical trials","volume":"8","author":"Petri","year":"1999","journal-title":"Lupus"},{"key":"2026100119511907500_keag522-B74","doi-asserted-by":"crossref","first-page":"keaf624","DOI":"10.1093\/rheumatology\/keaf624","article-title":"Establishing a consensus definition of VEXAS flare for clinical research","volume":"65","author":"Weeks","year":"2026","journal-title":"Rheumatology"},{"key":"2026100119511907500_keag522-B75","first-page":"288","article-title":"Systemic lupus erythematosus disease activity index 2000","volume":"29","author":"Gladman","year":"2002","journal-title":"J Rheumatol"},{"key":"2026100119511907500_keag522-B76","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/art.1780350606","article-title":"Derivation of the SLEDAI. A disease activity index for lupus patients","volume":"35","author":"Bombardier","year":"1992","journal-title":"Arthritis Rheum"},{"key":"2026100119511907500_keag522-B77","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1136\/annrheumdis-2018-214140","article-title":"Comparing patient-perceived and physician-perceived remission and low disease activity in psoriatic arthritis: an analysis of 410 patients from 14 countries","volume":"78","author":"Gorlier","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2026100119511907500_keag522-B78","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1136\/ard.2010.143743","article-title":"EULAR Sj\u00f6gren\u2019s Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sj\u00f6gren\u2019s syndrome","volume":"70","author":"Seror","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2026100119511907500_keag522-B79","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/bjd.21647","article-title":"International consensus definition of disease flare in hidradenitis suppurativa","volume":"187","author":"LeWitt","year":"2022","journal-title":"Br J Dermatol"},{"key":"2026100119511907500_keag522-B80","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/j.cgh.2019.09.021","article-title":"Discordance between patient-reported outcomes and mucosal inflammation in patients with mild to moderate ulcerative colitis","volume":"18","author":"Ma","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026100119511907500_keag522-B81","doi-asserted-by":"crossref","first-page":"e70295","DOI":"10.1111\/1756-185X.70295","article-title":"Classification in idiopathic inflammatory myopathies: where are we now?","volume":"28","author":"Shivakumar","year":"2025","journal-title":"Int J Rheum Dis"},{"key":"2026100119511907500_keag522-B82","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1002\/art.43429","article-title":"Relapse rate after glucocorticoid-free remission in patients with idiopathic inflammatory myopathies and validation of the international myositis assessment and clinical studies group criteria for complete clinical response and worsening","volume":"78","author":"Tsuji","year":"2026","journal-title":"Arthritis Rheumatol"},{"key":"2026100119511907500_keag522-B83","first-page":"188","article-title":"Retrospective analysis of the outcome of patients with idiopathic inflammatory myopathy: a long-term follow-up study","volume":"32","author":"Taborda","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"2026100119511907500_keag522-B84","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1007\/s10067-025-07398-9","article-title":"Clinical features and risk factors of flare in anti-synthetase syndrome","volume":"44","author":"Hasegawa","year":"2025","journal-title":"Clin Rheumatol"},{"key":"2026100119511907500_keag522-B85","doi-asserted-by":"crossref","first-page":"e70469","DOI":"10.1111\/1756-185x.70469","article-title":"High frequency of muscle activity relapses in anti-Jo-1 antisynthetase syndrome","volume":"28","author":"Choma","year":"2025","journal-title":"Int J Rheum Dis"},{"key":"2026100119511907500_keag522-B86","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/ana.22477","article-title":"A randomized, pilot trial of etanercept in dermatomyositis","volume":"70","author":"The Muscle Study Group","year":"2011","journal-title":"Ann Neurol"},{"key":"2026100119511907500_keag522-B87","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/art.37754","article-title":"Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial","volume":"65","author":"Oddis","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2026100119511907500_keag522-B88","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1136\/annrheumdis-2017-211751","article-title":"Abatacept in the treatment of adult dermatomyositis and polymyositis: a randomised, phase IIb treatment delayed-start trial","volume":"77","author":"Tj\u00e4rnlund","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2026100119511907500_keag522-B89","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.semarthrit.2017.10.010","article-title":"A randomized, double-blind, placebo-controlled trial of infliximab in refractory polymyositis and dermatomyositis","volume":"47","author":"Schiffenbauer","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"2026100119511907500_keag522-B90","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa2117912","article-title":"Trial of intravenous immune globulin in dermatomyositis","volume":"387","author":"Aggarwal","year":"2022","journal-title":"N Engl J Med"},{"key":"2026100119511907500_keag522-B91","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1002\/acr2.11493","article-title":"Randomized trial of tocilizumab in the treatment of refractory adult polymyositis and dermatomyositis","volume":"4","author":"Oddis","year":"2022","journal-title":"ACR Open Rheumatol"},{"key":"2026100119511907500_keag522-B92","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/rheumatology\/kead281","article-title":"Belimumab treatment of adult idiopathic inflammatory myopathy","volume":"63","author":"Marder","year":"2024","journal-title":"Rheumatology"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keag522\/71227940\/keag522.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/65\/10\/keag522\/71227940\/keag522.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/65\/10\/keag522\/71227940\/keag522.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T23:51:37Z","timestamp":1790898697000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/doi\/10.1093\/rheumatology\/keag522\/8817546"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,18]]},"references-count":92,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keag522","relation":{},"ISSN":["1462-0332"],"issn-type":[{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,9,18]]},"article-number":"keag522"}}